Drug-induced lipodystrophy

ORPHA: 901571 Treatment Available

Overview

medical condition

Available Treatments (1)

DrugFormStatusCountriesLead Time
Metreleptin
Orphan Cold Chain
Subcutaneous injection, 11.3mg powder for reconstitutionFDA Approved621d

Clinical Presentation

Signs and symptoms associated with Drug-induced lipodystrophy, sourced from HPO and Orphanet clinical annotations.

LipoatrophyReduced subcutaneous adipose tissueAbsence of subcutaneous fatHyperpigmentation of the skinHypopigmentation of the skinErythema

Classification & Codes

Orphanet Code

ORPHA:90157
Drug-induced lipodystrophy
OrphanetORPHA:90157
Treatments1 drug(s)
Symptoms on record6 signs
Statuspublished

Treatment Summary

Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO